Biotech Values

[DewDiligence]

BMY—...on recent investor calls it's sounded like they were conducting a hierarchical analysis that would have started at higher cutoffs.

I listened to all the recent calls and didn't get that impression; rather, I was unable to infer what the primary endpoint was, and I thought BMY was playing its cards unduly close to the vest for reasons that weren't entirely clear.